Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC

J Thorac Oncol. 2021 Apr;16(4):532-536. doi: 10.1016/j.jtho.2020.12.021.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Aminopyridines
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Humans
  • Lactams
  • Lactams, Macrocyclic
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles
  • Receptor Protein-Tyrosine Kinases / genetics

Substances

  • Aminopyridines
  • Lactams
  • Lactams, Macrocyclic
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Receptor Protein-Tyrosine Kinases
  • lorlatinib